Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Recruiting 2Completed 2Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 4354Neoplasms 3056Prostatic Neoplasms 1904Colorectal Neoplasms 1739Lung Neoplasms 1555Carcinoma, Non-Small-Cell Lung 1270Pancreatic Neoplasms 981Leukemia, Myeloid, Acute 952Multiple Myeloma 951Lymphoma 912Head and Neck Neoplasms 894Leukemia 852Precursor Cell Lymphoblastic Leukemia-Lymphoma 833Neoplasm Metastasis 793Colonic Neoplasms 785Carcinoma, Hepatocellular 762Ovarian Neoplasms 757Melanoma 752Stomach Neoplasms 742Rectal Neoplasms 701Brain Neoplasms 696Lymphoma, Non-Hodgkin 663Leukemia, Lymphocytic, Chronic, B-Cell 618Uterine Cervical Neoplasms 607Lymphoma, Follicular 559Glioblastoma 541Recurrence 539Hodgkin Disease 532Esophageal Neoplasms 527Myelodysplastic Syndromes 508

Interventions

ublituximab 1LFB-R603 1Interferon beta-1a 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × OTHER × Optic Neuritis × Clear all
NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Johns Hopkins University

Phase 1 Completed
6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

NCT00179478 2017-09-06

CHAMPIONS10

Beth Israel Deaconess Medical Center

Phase 4 Completed
155 enrolled 10 charts

Cerebellar Diseases, Multiple Sclerosis, Myelitis, Transverse, Optic Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡